| 353.22 3.15 (0.9%) | 10-04 10:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 414.83 | 1-year : | 427.58 |
| Resists | First : | 355.17 | Second : | 366.07 |
| Pivot price | 353.09  |
|||
| Supports | First : | 337.51 | Second : | 280.81 |
| MAs | MA(5) : | 354.04 |
MA(20) : | 350.69 |
| MA(100) : | 321.84 |
MA(250) : | 267.45 |
|
| MACD | MACD : | 3 |
Signal : | 3.8 |
| %K %D | K(14,3) : | 54.7 |
D(3) : | 64.4 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 366.07 | Low : | 208.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ UTHR ] has closed above bottom band by 42.5%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 357.85 - 360.35 | 360.35 - 362.27 |
| Low: | 342.21 - 345.6 | 345.6 - 348.21 |
| Close: | 345.4 - 349.97 | 349.97 - 353.48 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Thu, 03 Oct 2024
(UTHR) Investment Report - Stock Traders Daily
Thu, 03 Oct 2024
A Look Into United Therapeutics Inc's Price Over Earnings - Benzinga
Thu, 03 Oct 2024
United Therapeutics Corporation (UTHR): Why Are Hedge Funds Bullish On This Cheap Growth Stock Right Now? - Yahoo Finance
Wed, 02 Oct 2024
United Therapeutics CFO sells over $2.3m in company stock - Investing.com
Fri, 27 Sep 2024
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price - Simply Wall St
Fri, 06 Sep 2024
United Therapeutics Corporation's (NASDAQ:UTHR) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 105.7 (%) |
| Shares Short | 4,080 (K) |
| Shares Short P.Month | 4,140 (K) |
| EPS | 21.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 128.25 |
| Profit Margin | 40.8 % |
| Operating Margin | 44.7 % |
| Return on Assets (ttm) | 11.7 % |
| Return on Equity (ttm) | 19.2 % |
| Qtrly Rev. Growth | 19.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 58.88 |
| EBITDA (p.s.) | 29.89 |
| Qtrly Earnings Growth | 11.6 % |
| Operating Cash Flow | 1,110 (M) |
| Levered Free Cash Flow | 650 (M) |
| PE Ratio | 16.15 |
| PEG Ratio | 0.8 |
| Price to Book value | 2.74 |
| Price to Sales | 5.96 |
| Price to Cash Flow | 14.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|